CA2108401A1 - Recepteur induit par l'activation de lymphocytes dans la reaction inflammatoire - Google Patents

Recepteur induit par l'activation de lymphocytes dans la reaction inflammatoire

Info

Publication number
CA2108401A1
CA2108401A1 CA 2108401 CA2108401A CA2108401A1 CA 2108401 A1 CA2108401 A1 CA 2108401A1 CA 2108401 CA2108401 CA 2108401 CA 2108401 A CA2108401 A CA 2108401A CA 2108401 A1 CA2108401 A1 CA 2108401A1
Authority
CA
Canada
Prior art keywords
ila
vector
sequence
cell
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2108401
Other languages
English (en)
Inventor
Martin Lotz
Herbert Schwarz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CA2108401A1 publication Critical patent/CA2108401A1/fr
Abandoned legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA 2108401 1993-09-27 1993-10-14 Recepteur induit par l'activation de lymphocytes dans la reaction inflammatoire Abandoned CA2108401A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12769393A 1993-09-27 1993-09-27
US08/127,693 1993-09-27

Publications (1)

Publication Number Publication Date
CA2108401A1 true CA2108401A1 (fr) 1995-03-28

Family

ID=22431451

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2108401 Abandoned CA2108401A1 (fr) 1993-09-27 1993-10-14 Recepteur induit par l'activation de lymphocytes dans la reaction inflammatoire

Country Status (1)

Country Link
CA (1) CA2108401A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874240A (en) * 1996-03-15 1999-02-23 Human Genome Sciences, Inc. Human 4-1BB receptor splicing variant
WO1999044629A3 (fr) * 1998-07-15 2000-01-06 Merckle Gmbh Utilisation du facteur cd137 pour la stimulation de la proliferation de monocytes peripheriques
WO2003031474A3 (fr) * 2001-10-04 2003-10-16 Herbert Schwarz Cd137 en tant que facteur de proliferation pour cellules souches hematopoietiques
US7138500B1 (en) 1993-05-07 2006-11-21 Immunex Corporation Antibodies to human 4-1BB
US7211259B1 (en) 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US10279038B2 (en) 2017-07-11 2019-05-07 Compass Therapeutics Llc Agonist antibodies that bind human CD137 and uses thereof
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138500B1 (en) 1993-05-07 2006-11-21 Immunex Corporation Antibodies to human 4-1BB
US7211259B1 (en) 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
US5874240A (en) * 1996-03-15 1999-02-23 Human Genome Sciences, Inc. Human 4-1BB receptor splicing variant
WO1999044629A3 (fr) * 1998-07-15 2000-01-06 Merckle Gmbh Utilisation du facteur cd137 pour la stimulation de la proliferation de monocytes peripheriques
US6627200B1 (en) * 1998-07-15 2003-09-30 Merckle Gmbh Utilization of CD 137 in order to promote the proliferation of peripheral monocytes
WO2003031474A3 (fr) * 2001-10-04 2003-10-16 Herbert Schwarz Cd137 en tant que facteur de proliferation pour cellules souches hematopoietiques
US9382328B2 (en) 2003-10-10 2016-07-05 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US7659384B2 (en) 2003-10-10 2010-02-09 Bristol-Myers Squibb Company Polynucleotides encoding fully human antibodies against human 4-1BB
US8137667B2 (en) 2003-10-10 2012-03-20 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US8716452B2 (en) 2003-10-10 2014-05-06 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US10279039B2 (en) 2017-07-11 2019-05-07 Compass Therapeutics Llc Agonist antibodies that bind human CD137 and uses thereof
US10279040B1 (en) 2017-07-11 2019-05-07 Compass Therapeutics Llc Agonist antibodies that bind human CD137 and uses thereof
US10279038B2 (en) 2017-07-11 2019-05-07 Compass Therapeutics Llc Agonist antibodies that bind human CD137 and uses thereof
US10350292B1 (en) 2017-07-11 2019-07-16 Compass Therapeutics Llc Agonist antibodies that bind human CD137 and uses thereof
US10434175B2 (en) 2017-07-11 2019-10-08 Compass Therapeutics Llc Agonist antibodies that bind human CD137 and uses thereof
US10716851B2 (en) 2017-07-11 2020-07-21 Compass Therapeutics Llc Agonist antibodies that bind human CD137 and uses thereof
US11752207B2 (en) 2017-07-11 2023-09-12 Compass Therapeutics Llc Agonist antibodies that bind human CD137 and uses thereof
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
US12286483B2 (en) 2017-10-31 2025-04-29 Compass Therapeutics Llc Method of treating cancer using CD137 antibodies and PD-1 antagonists
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof

Similar Documents

Publication Publication Date Title
US6348574B1 (en) Seven transmembrane receptors
US7025962B1 (en) Mammalian cell surface antigens; related reagents
AU768475B2 (en) Interleukin 17-like receptor protein
KR0174540B1 (ko) T세포 항원 수용체의 지어부위와 반응하는 단클론항체
US5753225A (en) Antibodies that mimic actions of neurotrophins
AU743490B2 (en) NTN-2 member of TNF ligand family
US7858094B2 (en) TREM-1 splice variant for use in modifying immune responses
AU7608898A (en) Ntn-2 member of tnf ligand family
US20120207752A1 (en) Methods for modulating il-33 activity
BG65519B1 (bg) Белтъци, свързващи интерлевкин-18, тяхното получаване и приложение
Wong et al. T cell receptor signals enhance susceptibility to Fas-mediated apoptosis
US6265160B1 (en) Method of identifying inhibitors of the Jak-Stat signal transduction pathway
AU8767698A (en) Novel orphan receptor
CA2108401A1 (fr) Recepteur induit par l'activation de lymphocytes dans la reaction inflammatoire
WO1995008629A1 (fr) Sequence de proteines ou facteurs de reconnaissance de recepteurs et leur procede d'utilisation
EP1220919A2 (fr) C4.4a, antigene associee a la metastase
HK1011548A (en) Novel v31 seven transmembrane receptors
HK1021502A (en) Monoclonal antibodies reactive with defined regions of the t cell antigen receptor
IL108742A (en) Active monoclonal antibodies with defined regions of the T cell antibody receptor

Legal Events

Date Code Title Description
FZDE Discontinued